Our Company

NeoBiotechnologies is a leader in advancing immuno-oncology research and transforming cancer treatment. We are committed to collaboration, actively engaging in partnerships with researchers and institutions worldwide to optimize our antibodies. Our commitment to innovation and quality places us at the forefront of immuno-oncology research, continuously pushing the boundaries of cancer diagnostics and scientific discovery.

Driving Breakthroughs in Immuno-Oncology Research

NeoBiotechnologies stands out for its comprehensive range of high-quality, validated antibodies and cutting-edge technology. Our diverse product portfolio is technologically advanced and designed to give researchers the precise tools they need to investigate protein functions, interactions, and expression patterns.

Advanced Antibody Portfolio

Our extensive product range includes over 10,000 monoclonal antibody products targeting various types of cancer, including solid tumors and hematological malignancies. Produced using hybridoma and advanced recombinant techniques—which involve cloning specific antibody-producing cells and incorporating their variable CDRs—our antibodies are renowned for their lot-to-lot consistency and precision.

We offer a technologically advanced portfolio tailored for diverse research applications:

Rigorous Validation Processes

Quality and reliability are at the core of our manufacturing. To ensure antibody specificity, epitope mapping, binding affinity, and reproducibility, our products undergo rigorous testing. This includes evaluation on the high-throughput HuProt™ Protein Array, which contains over 21,000 full-length proteins to meticulously assess potential cross-reactivity.

We ensure top-tier reliability through extensive validation methods (SDS-PAGE, Flow Cytometry, Purity/Sequencing) and are the original manufacturer of several key cancer biomarkers:

IHC on FFPE Tissues and Tissue Microarrays
HuProtTM Human Protein Array Validation
Epitope Mapping
Knockout/Knockdown Validation
Western Blot, SDS-Page, and Flow Cytometry
ELISA Matched Antibody Pairs
Sequencing

Our Leaders

Dr. Atul K. Tandon, PhD

President and CEO

Anshul Kundani

Vice President, Strategic Partnerships

Our Team

We believe that advancing immuno-oncology and delivering cutting-edge, highly validated research tools is only possible when we have the most dedicated experts on our teams.

Original Manufacturer with Custom Bulk Quantities Available

Get the original product straight from the manufacturer, ensuring long-term supply for your unique research needs.

Sequencing with Full Licensing Rights

Ideal for biotech and pharma partners seeking commercial use. We sequence our clones to maintain a stable supply of antibodies and to provide you with reproducible, reliable data.